Catalog No.: PC-61482Not For Human Use, Lab Use Only.
TAI-95 (T-1101, TAI 95) is a potent, orally abioavailable Hec1 inhibitor that disrupts Hec1-Nek2 protein interaction wide anti-cancer spectrum (GI50=14.29-73.65 nM, breast cancer cell lines).
TAI-95 (T-1101, TAI 95) is a potent, orally abioavailable Hec1 inhibitor that disrupts Hec1-Nek2 protein interaction wide anti-cancer spectrum (GI50=14.29-73.65 nM, breast cancer cell lines).
TAI-95 (T-1101) demonstrates strong inhibition of in vivo tumor growth of breast cancer models without inducing weight loss or other obvious toxicity.
TAI-95 (T-1101) induces apoptotic cell death, shows activity on MDR cell lines and leads to downregulation of the expression of P-glycoprotein (Pgp),.
TAI-95 (T-1101) also increases the potency of cytotoxic Pgp substrates, including doxorubicin and topotecan.
